WO2000041472A3 - Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine - Google Patents

Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine Download PDF

Info

Publication number
WO2000041472A3
WO2000041472A3 PCT/EP2000/000142 EP0000142W WO0041472A3 WO 2000041472 A3 WO2000041472 A3 WO 2000041472A3 EP 0000142 W EP0000142 W EP 0000142W WO 0041472 A3 WO0041472 A3 WO 0041472A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding partners
migraine
receptors
treatment
methods
Prior art date
Application number
PCT/EP2000/000142
Other languages
German (de)
English (en)
Other versions
WO2000041472A2 (fr
Inventor
Francisco Javier Garcia-Ladona
Original Assignee
Knoll Ag
Garcia Ladona Francisco Javier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag, Garcia Ladona Francisco Javier filed Critical Knoll Ag
Priority to AU22891/00A priority Critical patent/AU2289100A/en
Priority to MXPA01006986A priority patent/MXPA01006986A/es
Priority to EP00901526A priority patent/EP1144050A2/fr
Priority to CA2359360A priority patent/CA2359360C/fr
Priority to JP2000593096A priority patent/JP2002540063A/ja
Publication of WO2000041472A2 publication Critical patent/WO2000041472A2/fr
Publication of WO2000041472A3 publication Critical patent/WO2000041472A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des partenaires de liaison sélectifs pour les récepteurs 5-HT5, ainsi que des procédés d'identification et de caractérisation de tels partenaires de liaison, notamment des procédés de criblage. Elle concerne également des compositions pharmaceutiques contenant ces partenaires de liaison, et leur utilisation pour le traitement d'affections cérébrovasculaires, telles que la migraine.
PCT/EP2000/000142 1999-01-11 2000-01-11 Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine WO2000041472A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU22891/00A AU2289100A (en) 1999-01-11 2000-01-11 Binding partners for 5-ht5-receptors for the treatment of migraine
MXPA01006986A MXPA01006986A (es) 1999-01-11 2000-01-11 Contrapartes de union de los receptores 5-ht5 para tratamiento de migrana.
EP00901526A EP1144050A2 (fr) 1999-01-11 2000-01-11 Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine
CA2359360A CA2359360C (fr) 1999-01-11 2000-01-11 Methode de criblage in vitro permettant d'identifier des partenaires de liaison selective pour recepteurs 5-ht5
JP2000593096A JP2002540063A (ja) 1999-01-11 2000-01-11 偏頭痛治療のための５−ｈｔ５受容体のための結合パートナー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900674A DE19900674A1 (de) 1999-01-11 1999-01-11 Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung
DE19900674.1 1999-01-11

Publications (2)

Publication Number Publication Date
WO2000041472A2 WO2000041472A2 (fr) 2000-07-20
WO2000041472A3 true WO2000041472A3 (fr) 2001-10-11

Family

ID=7893919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/000142 WO2000041472A2 (fr) 1999-01-11 2000-01-11 Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine

Country Status (8)

Country Link
EP (1) EP1144050A2 (fr)
JP (1) JP2002540063A (fr)
CN (1) CN1321635C (fr)
AU (1) AU2289100A (fr)
CA (1) CA2359360C (fr)
DE (1) DE19900674A1 (fr)
MX (1) MXPA01006986A (fr)
WO (1) WO2000041472A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
WO2007022947A2 (fr) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
EP1917244A2 (fr) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105192A (en) * 1981-08-27 1983-03-23 Shaun R Coughlin Composition for use in treating atherosclerosis
WO1994001555A1 (fr) * 1992-07-01 1994-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations
WO1994018319A1 (fr) * 1993-02-09 1994-08-18 Institut National De La Sante Et De La Recherche Medicale Nouveaux polypeptides ayant une activite de recepteur serotoninergique, acides nucleiques codant pour ces polypeptides et utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360735A (en) * 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105192A (en) * 1981-08-27 1983-03-23 Shaun R Coughlin Composition for use in treating atherosclerosis
WO1994001555A1 (fr) * 1992-07-01 1994-01-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides ayant une activite de recepteur serotoninergique (5ht5a), acides nucleiques codant pour ces polypeptides et utilisations
WO1994018319A1 (fr) * 1993-02-09 1994-08-18 Institut National De La Sante Et De La Recherche Medicale Nouveaux polypeptides ayant une activite de recepteur serotoninergique, acides nucleiques codant pour ces polypeptides et utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Martindale", PHARMACEUTICAL PRESS, LONDON, XP002140026, 1993 *
CARSON: "the 5ht5a...", GLIA, vol. 17, no. 4, 1996, pages 317 - 326, XP000913723 *
See also references of EP1144050A2 *
SHIMRON: "human 5ht5...", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 233, no. 1, 1997, pages 6 - 9, XP000907456 *
WEISS: "expression of...", METHODS IN MOLECULAR BIOLOGY, vol. 103, 1998, pages 227 - 239, XP002140017 *

Also Published As

Publication number Publication date
JP2002540063A (ja) 2002-11-26
AU2289100A (en) 2000-08-01
DE19900674A1 (de) 2000-07-13
MXPA01006986A (es) 2002-09-18
CA2359360A1 (fr) 2000-07-20
CN1342070A (zh) 2002-03-27
CN1321635C (zh) 2007-06-20
CA2359360C (fr) 2012-11-27
EP1144050A2 (fr) 2001-10-17
WO2000041472A2 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
WO2005055944A3 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
WO2005016962A3 (fr) Compositions et techniques de traitement de maladies liees a l'immunite
WO2004011611A3 (fr) Anticorps anti-taci et utilisations de ceux-ci
WO2001098317A3 (fr) Alpha-glycosylceramides destines au traitement d'infections bacteriennes et fongiques
WO2002089738A3 (fr) Composes proteomimetiques et procedes correspondants
WO2003016475A3 (fr) Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur
EP1777234A3 (fr) Méthodes de traitement des maladies inflammatoires en utilisant des liants spécifiques de l'angiopoietin-2 humain
WO2003057134A3 (fr) Agents de liaison specifiques de l'angiopoietine-2 humaine
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
WO2004113275A3 (fr) Methodes et compositions pour traiter les maladies liees a l'amyloide
WO2002040702A3 (fr) Methodes de traitement du cancer et d'autres maladies et procedes permettant de developper ces methodes
WO2004091572A3 (fr) Compositions contenant des structures cochleaires, dirigees contre l'expression de proteines
WO2007059341A3 (fr) Modulateurs de la proteine kinase a base de pyrazolothiazole
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2005089294A3 (fr) Synthese d'indenoisoquinoliniums et techniques d'utilisation
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2002068476A3 (fr) Composition et procede de traitement de troubles inflammatoires
WO2005000207A3 (fr) Anticorps du recepteur du pcdgf et procede d'utilisation associe
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2001015677A3 (fr) Utilisation d'agonistes de 5-ht1b/1d pour le traitement des douleurs oculaires
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2004101766A3 (fr) Compositions a base de grp94 et procedes d'utilisation associes
WO2000041472A3 (fr) Partenaires de liaison pour les recepteurs 5-ht5 utilises pour le traitement de la migraine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804610.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09869814

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2359360

Country of ref document: CA

Ref document number: 2359360

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 593096

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006986

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000901526

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000901526

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642